Galenica Sante AG (GALE) Fair Value & Analysis
Healthcare · CH · Market cap CHF 4.3B · ISIN CH0360674466
What is Galenica Sante AG really worth?
A solid business, but trading 34% above our fair value of CHF 61.79.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 25 valuation models · updated 22 days ago
Share price −2.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (CHF 77.24). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range CHF 57.79 – CHF 101.34 · fair‑value band CHF 46.34 – CHF 77.24 · the CHF 82.90 price screens above the CHF 61.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Galenica Sante AG (GALE) currently trades at CHF 82.90, while our model-based Fair Value estimate is CHF 61.79, implying the stock looks roughly 34.2% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of CHF 67.99 per share, and 1 of the 25 models we run sit above the CHF 82.90 price. Bear case: the Asset-Based group reads lowest at CHF 19.93, and 24 of the 25 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Galenica Sante AG generated revenue of CHF 4.1B at a net margin of 4.4%. Revenue grew 5.8% year over year. It earns a return on equity of 12.1%. Net debt stands at CHF 945M. Fundamentals as of Aug 13, 2026
Our scenario range runs from CHF 46.34 (bear case) to CHF 77.24 (bull case); at CHF 82.90, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 36% fair-value upside, at −25%, GALE screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly CHF 0.7850 per share, which is 1.3 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 25 models by family
Widest divergence: DCF Models (CHF 67.99) versus Asset-Based (CHF 19.93). Highest evidence: FCF DCF (80).
Notify me when GALE reaches fair value
Put GALE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice.
Full company description
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and products through various distribution channels. The Logistics & IT segment provides various specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers master data systems for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as offers complete management solutions for pharmacies. In addition, it provides on-schedule delivery services to pharmacies, drugstores, doctors, hospitals, and care homes. The company was founded in 1927 and is headquartered in Bern, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Galenica Sante AG reported revenue of CHF 4.1B in FY2025 versus CHF 3.8B in FY2021, a compound +1.9%/yr. Reported net income was CHF 181M in FY2025, compounding +1.9%/yr from FY2021.
of which total revenue +3.4 % · buybacks/dilution +0.0 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
GALE screens 34% overvalued. Compare with McKesson Corporation →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Galenica Ltd (WBO:GALE) (H1 2026) Earnings Call Highlights: Strong Core Growth and Strategic ...
- Galenica AG (VTX:GALE) Shares Could Be 33% Below Their Intrinsic Value Estimate
- Institutions own 45% of Galenica AG (VTX:GALE) shares but retail investors control 55% of the company
- Galenica AG's (VTX:GALE) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Peer Group
Medical Distribution · 78 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $906.77 | $819.31 | −10% |
| Cencora, Inc COR | $330.97 | $211.07 | −36% |
| Cardinal Health, Inc CAH | $234.55 | $141.77 | −40% |
| Henry Schein, Inc HSIC | $88.46 | $71.70 | −19% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.37 | ¥33.96 | +107% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.03 | ¥28.65 | +36% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 74.40 | kr 28.26 | −62% |
| China National Medicines Corporation 600511 | ¥26.84 | ¥58.22 | +117% |
Compare Galenica Sante AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Galenica Sante AG (GALE) overvalued or undervalued?
What is the fair value of GALE?
What is the quality score of GALE?
What is the revenue of Galenica Sante AG (GALE)?
What is the net profit margin of GALE?
Does Galenica Sante AG pay a dividend?
Watch Galenica Sante AG in the live analysis
One click puts Galenica Sante AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.